Actively Recruiting
Comparing Aspirin and Clopidogrel to Prevent Leaflet Clots After Transcatheter Aortic Valve Replacement in Severe Aortic Stenosis
Led by Yonsei University · Updated on 2026-06-30
270
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the best antithrombotic therapy after transcatheter aortic valve replacement TAVR for patients with severe aortic stenosis. The study compares aspirin versus clopidogrel as single antiplatelet therapies to prevent leaflet thrombosis, a complication that can affect the valve after TAVR. This is a prospective, multicenter, open-label, randomized controlled trial designed to answer this important clinical question. All participants will first receive dual antiplatelet therapy consisting of aspirin 100 mg and clopidogrel 75 mg daily for 4 weeks following TAVR. After this period, they will be randomly assigned to continue with either aspirin alone or clopidogrel alone as monoantiplatelet therapy. The study uses cardiac computed tomography CT and transthoracic echocardiography to assess leaflet thrombosis at 3 months post-TAVR. Clinical follow-up will continue for 6 months. During the trial, participants will undergo imaging tests at 3 months to measure the incidence of leaflet thrombosis. Secondary assessments include monitoring for strokes, transient ischemic attacks, thromboembolic events, and bleeding complications up to 6 months after TAVR. Echocardiographic parameters such as valve pressure gradients and regurgitation will also be evaluated. The total participation time spans 6 months with regular clinical follow-up visits to monitor health and treatment outcomes.
CONDITIONS
Brief Title
Aspirin vs Clopidogrel After TAVR
Research Team
Y
Young-Guk Ko, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here